Literature DB >> 18175274

Microbioreactors for high-throughput cytotoxicity assays.

Shang-Tian Yang1, Xudong Zhang, Yuan Wen.   

Abstract

Cell culture plays a fundamental role in the biotechnology and pharmaceutical industries, impacting both drug discovery and manufacturing as well as regenerative medicine. In drug discovery, cell-based assays are increasingly being used for drug target validation and drug ADMET (absorption, distribution, metabolism, elimination and toxicity) studies because cells can provide more representative responses to drugs than simple molecular assays and are easier to use in a high-throughput format than animals. There are, however, intrinsic drawbacks associated with conventional in vitro cellular tests using two-dimensional cultures, in that they lack a three-dimensional (3D) scaffold to support cell growth and proper tissue function, and cannot mimic in vivo cellular conditions. Tailoring scaffold properties for 3D cell cultures is therefore essential in developing a representative in vitro tissue model for cytotoxicity assays. Recently, microfluidic bioreactors with miniaturized culturing vessels and high controllability for operation and on-line monitoring/sensing have gained popularity in bioprocess development and cell-based assays. The advancement in this field has been enabled by the development of novel cell lines and reporter gene techniques, as well as new microfabrication, microfluidics and optical and electrochemical sensor technologies. Non-invasive detection methods using reporter genes and label-free techniques allow for real-time dynamic monitoring of viable cell number and cellular activities. Microbioreactors with continuous perfusion allow for long-term culturing to study chronic toxicity effects. Systemic toxicity and interactions between different cell types can also be studied on a biochip. High-density microfluidic arrays provide a platform for future high-throughput and high-content screening that will contribute to drug discovery and bioprocess development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175274

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  8 in total

1.  Microfluidic heart on a chip for higher throughput pharmacological studies.

Authors:  Ashutosh Agarwal; Josue Adrian Goss; Alexander Cho; Megan Laura McCain; Kevin Kit Parker
Journal:  Lab Chip       Date:  2013-09-21       Impact factor: 6.799

Review 2.  High-content drug screening with engineered musculoskeletal tissues.

Authors:  Herman Vandenburgh
Journal:  Tissue Eng Part B Rev       Date:  2010-02       Impact factor: 6.389

3.  Upcyte® microvascular endothelial cells repopulate decellularized scaffold.

Authors:  Katharina Scheller; Iris Dally; Nadja Hartmann; Bernhard Münst; Joris Braspenning; Heike Walles
Journal:  Tissue Eng Part C Methods       Date:  2012-09-13       Impact factor: 3.056

4.  Study of Chemotaxis and Cell-Cell Interactions in Cancer with Microfluidic Devices.

Authors:  Jiqing Sai; Matthew Rogers; Kathryn Hockemeyer; John P Wikswo; Ann Richmond
Journal:  Methods Enzymol       Date:  2015-11-24       Impact factor: 1.600

Review 5.  Organ-on-a-chip platforms for studying drug delivery systems.

Authors:  Nupura S Bhise; João Ribas; Vijayan Manoharan; Yu Shrike Zhang; Alessandro Polini; Solange Massa; Mehmet R Dokmeci; Ali Khademhosseini
Journal:  J Control Release       Date:  2014-05-10       Impact factor: 9.776

6.  Biomaterials-based electronics: polymers and interfaces for biology and medicine.

Authors:  Meredith Muskovich; Christopher J Bettinger
Journal:  Adv Healthc Mater       Date:  2012-04-05       Impact factor: 9.933

Review 7.  Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues.

Authors:  A Chen; M L Yarmush; T Maguire
Journal:  Curr Drug Metab       Date:  2012-07       Impact factor: 3.731

8.  Tissue engineering of a human 3D in vitro tumor test system.

Authors:  Corinna Moll; Jenny Reboredo; Thomas Schwarz; Antje Appelt; Sebastian Schürlein; Heike Walles; Sarah Nietzer
Journal:  J Vis Exp       Date:  2013-08-06       Impact factor: 1.355

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.